Incidence of gastrointestinal bleeding after transesophageal echocardiography in patients with gastroesophageal varices: A systematic review and meta-analysis

2021 ◽  
Author(s):  
Rex Wan-Hin Hui ◽  
Choy-May Leung
Keyword(s):  
Systematic Review ◽  
Gastrointestinal Bleeding ◽  
Transesophageal Echocardiography ◽  
Meta Analysis ◽  
Gastroesophageal Varices

Tranexamic Acid in Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Joanna C. Dionne ◽  
Simon JW Oczkowski ◽  
Beverley J. Hunt ◽  
Massimo Antonelli ◽  
Marije Wijnberge ◽  
...  
Keyword(s):  
Systematic Review ◽  
Gastrointestinal Bleeding ◽  
Tranexamic Acid ◽  
Meta Analysis

scholarly journals Use of hemostatic powder in treatment of upper gastrointestinal bleeding: a systematic review and meta-analysis

2019 ◽  
Vol 07 (12) ◽  
pp. E1704-E1713 ◽  
Author(s):  
Daniel Tavares de Rezende ◽  
Vitor Ottoboni Brunaldi ◽  
Wanderley Marques Bernardo ◽  
Igor Braga Ribeiro ◽  
Raquel Cristina Lins Mota ◽  
...  
Keyword(s):  
Systematic Review ◽  
Gastrointestinal Bleeding ◽  
Latin American ◽  
Upper Gastrointestinal Bleeding ◽  
Rescue Therapy ◽  
Meta Analysis ◽  
Secondary Outcome ◽  
Primary Hemostasis ◽  
Hemostatic Powder ◽  
Upper Gastrointestinal

Abstract Background and study aims TC-325 is a novel mineral hemostatic powder that creates a mechanical barrier by absorbing blood components and promoting clotting. Recently approved for use in humans, it has shown promise for treatment of upper gastrointestinal bleeding (UGIB). However, because there have been no large studies of TC-325, its true efficacy and safety profile remain unknown. We performed a systematic review and meta-analysis to determine the safety and efficacy of TC-325 in treating UGIB, based on rates of initial hemostasis, rebleeding, and adverse events (AEs). Methods We searched the MEDLINE/PubMed, EMBASE, CENTRAL, Latin-American and Caribbean Health Sciences Literature databases, as well as the gray literature, to identify articles describing use of TC-325 up to October 2018. Primary outcomes were initial hemostasis and rebleeding. AEs were described as a secondary outcome. Risk of bias was assessed with international scores. Results We identified 2077 records after removal of duplicates. We included 50 studies, involving a collective total of 1445 patients, in the quantitative synthesis. Primary hemostasis and rebleeding rates were 90.7 % and 26.1 %, respectively. Subgroup analyses showed similar results. Only eight AEs were reported. Conclusions TC-325 appears to be a safe, effective treatment for UGIB. The overall rate of initial hemostasis after TC-325 use is high, regardless of etiology of bleeding or whether TC-325 is used as a primary or rescue therapy. Although it is also associated with high rebleeding rates, rates of AEs and equipment failure after TC-325 use are extremely low.

Efficacy of hemostatic powders in upper gastrointestinal bleeding: A systematic review and meta-analysis

2019 ◽  
Vol 51 (12) ◽  
pp. 1633-1640 ◽  
Author(s):  
Antonio Facciorusso ◽  
Marcelo Straus Takahashi ◽  
Ceren Eyileten Postula ◽  
Vincenzo Rosario Buccino ◽  
Nicola Muscatiello
Keyword(s):  
Systematic Review ◽  
Gastrointestinal Bleeding ◽  
Upper Gastrointestinal Bleeding ◽  
Meta Analysis ◽  
Upper Gastrointestinal

Angiotensin II antagonists and gastrointestinal bleeding in left ventricular assist devices: A systematic review and meta-analysis

2020 ◽  
pp. 039139882095181
Author(s):  
Veraprapas Kittipibul ◽  
Wasawat Vutthikraivit ◽  
Jakrin Kewcharoen ◽  
Pattara Rattanawong ◽  
Pakpoom Tantrachoti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Angiotensin Ii ◽  
Gastrointestinal Bleeding ◽  
Angiotensin Receptor Blockers ◽  
Meta Analysis ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Left Ventricular Assist Devices ◽  
Converting Enzyme Inhibitors

Gastrointestinal bleeding (GIB) especially from arteriovenous malformations (AVM) remains one of the devastating complications following continuous-flow left ventricular device (CF-LVAD) implantation. Blockade of angiotensin II pathway using angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) was reported to mitigate the risk of GIB and AVM-related GIB by suppressing angiogenesis. We performed a systematic review and meta-analysis to evaluate the association between ACEI/ARB treatment and GIB in CF-LVAD population. Comprehensive literature search was performed through December 2019. We included studies reporting risk of GIB and/or AVM-related GIB events in LVAD patients who received ACEI/ARB with those who did not. Data from each study were combined using the random-effects to calculate odd ratios and 95% confidence intervals. Three retrospective cohort studies were included in this meta-analysis involving 619 LVADs patients (467 patients receiving ACEI/ARB). The use of ACEI/ARB was statistically associated with decreased incidence of overall GIB (pooled OR 0.35, 95% CI 0.22–0.56, I2 = 0.0%, p < 0.001). There was a non-significant trend toward lower risk for AVM-related GIB in patients who received ACEI/ARB (pooled OR 0.46, 95% CI 0.19–1.07, I2 = 51%, p = 0.07). Larger studies with specific definitions of ACEI/ARB use and GIB are warranted to accurately determine the potential non-hemodynamic benefits of ACEI/ARB in CF-LVAD patients.

Sign in / Sign up

Export Citation Format

Share Document